A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of SOT101 in combination with cetuximab in patients with RAS wild-type colorectal cancer (AURELIO-05)
Latest Information Update: 07 Aug 2025
At a glance
- Drugs Cetuximab (Primary) ; Nanrilkefusp alfa (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms AURELIO-05
- Sponsors SOTIO
Most Recent Events
- 30 Jul 2024 Status changed from active, no longer recruiting to discontinued.
- 06 Mar 2024 Planned End Date changed from 1 Nov 2025 to 1 Nov 2024.
- 06 Mar 2024 Planned primary completion date changed from 1 Nov 2025 to 1 Aug 2024.